Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

Bioavailable 25OHD, total 25OHD, albumin, and DBP protein concentrations were measured in 89 samples from hospitalized patients and 42 healthy controls to determine how the DBP binding assay responds to differences in concentrations of DBP and compares to calculated bioavailable 25OHD values.

Source: Abstract. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Observational study.

Observational study

Observes exposures and outcomes without assigning the exposure; the subtype is not established here.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

This was a prospective observational study of hospitalized adults (age ≥18) recruited after admission to an intensive care unit.

Source: Methods.

Both hospitalized subject study and MACS study were conducted in compliance with the World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects, and approved by the Institutional Review Board of Massachusetts General Hospital and Massachusetts Institute of Technology, respectively.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Development and analytical validation of a novel bioavailable 25-hydroxyvitamin D assay

Observational study · PLoS ONE · 2021

Original publication title

Development and analytical validation of a novel bioavailable 25-hydroxyvitamin D assay

Anders H. Berg; Mahtab Tavasoli; Agnes S. Lo; Sherri-Ann M. Burnett-Bowie; Ishir Bhan; S. Ananth Karumanchi; Sahir Kalim; Dongsheng Zhang; Sophia Zhao; Ravi I. Thadhani

© 2021 Berg et al

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

The DBP-binding assay for bioavailable 25OHD shows expected changes in 25OHD % bioavailability in response to changes in DBP concentrations and concordance with calculated bioavailable 25OHD concentrations.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Bioavailable 25-hydroxyvitamin D (25OHD) may be a better indicator of vitamin D sufficiency than total 25OHD. This report describes a novel assay for measuring serum bioavailable 25OHD.

Source: Background

Abstract: What methods does the paper describe?

We developed an assay for 25OHD % bioavailability based on competitive binding of 25OHD tracer between vitamin D-binding protein (DBP)-coated affinity chromatography beads and serum DBP. Bioavailable 25OHD, total 25OHD, albumin, and DBP protein concentrations were measured in 89 samples from hospitalized patients and 42 healthy controls to determine how the DBP binding assay responds to differences in concentrations of DBP and compares to calculated bioavailable 25OHD values.

Source: Methods

Abstract: Results

DBP binding assay showed a linear relationship between DBP-bound 25OHD tracer recovered from bead supernatant and DBP calibrator concentrations (y = 0.0017x +0.731, R2 = 0.9961, p<0.001). Inversion of this relationship allowed interpolation of DBP binding equivalents based upon 25OHD tracer recovered. The relationship between DBP binding equivalents and % bioavailability fits a non-linear curve, allowing calculation of % bioavailable 25OHD from DBP binding equivalents (y = 10.625x-0.817, R2 = 0.9961, p<0.001). In hospitalized patient samples, there were linear relationships between DBP protein concentrations and DBP binding equivalents (y = 0.7905x + 59.82, R2 = 0.8597, p<0.001), between measured vs. calculated % bioavailability (y = 0.9528 + 0.0357, R2 = 0.7200, p<0.001), and between absolute concentrations of measured vs. calculated bioavailable 25OHD (y = 1.2403 + 0.1221, R2 = 0.8913, p<0.001).

Source: Results

Abstract: Conclusions

The DBP-binding assay for bioavailable 25OHD shows expected changes in 25OHD % bioavailability in response to changes in DBP concentrations and concordance with calculated bioavailable 25OHD concentrations.

Source: Conclusions
Authors’ abstract

Background

Bioavailable 25-hydroxyvitamin D (25OHD) may be a better indicator of vitamin D sufficiency than total 25OHD. This report describes a novel assay for measuring serum bioavailable 25OHD.

Methods

We developed an assay for 25OHD % bioavailability based on competitive binding of 25OHD tracer between vitamin D-binding protein (DBP)-coated affinity chromatography beads and serum DBP. Bioavailable 25OHD, total 25OHD, albumin, and DBP protein concentrations were measured in 89 samples from hospitalized patients and 42 healthy controls to determine how the DBP binding assay responds to differences in concentrations of DBP and compares to calculated bioavailable 25OHD values.

Results

DBP binding assay showed a linear relationship between DBP-bound 25OHD tracer recovered from bead supernatant and DBP calibrator concentrations (y = 0.0017x +0.731, R2 = 0.9961, p<0.001). Inversion of this relationship allowed interpolation of DBP binding equivalents based upon 25OHD tracer recovered. The relationship between DBP binding equivalents and % bioavailability fits a non-linear curve, allowing calculation of % bioavailable 25OHD from DBP binding equivalents (y = 10.625x-0.817, R2 = 0.9961, p<0.001). In hospitalized patient samples, there were linear relationships between DBP protein concentrations and DBP binding equivalents (y = 0.7905x + 59.82, R2 = 0.8597, p<0.001), between measured vs. calculated % bioavailability (y = 0.9528 + 0.0357, R2 = 0.7200, p<0.001), and between absolute concentrations of measured vs. calculated bioavailable 25OHD (y = 1.2403 + 0.1221, R2 = 0.8913, p<0.001).

Conclusions

The DBP-binding assay for bioavailable 25OHD shows expected changes in 25OHD % bioavailability in response to changes in DBP concentrations and concordance with calculated bioavailable 25OHD concentrations.

Publication and source details

Original title: Development and analytical validation of a novel bioavailable 25-hydroxyvitamin D assay

Anders H. Berg; Mahtab Tavasoli; Agnes S. Lo; Sherri-Ann M. Burnett-Bowie; Ishir Bhan; S. Ananth Karumanchi; Sahir Kalim; Dongsheng Zhang; Sophia Zhao; Ravi I. Thadhani

PLoS ONE · 2021

Competing Interests: Four of the authors on this manuscript (AB, RT, AK, and IB) are co-authors on a patent (WO2014179737A3, “Assays and methods of treatment relating to vitamin D insufficiency”). At the time of submission of this revised manuscript, this patent has not been licensed or otherwise used for commercial use by any of the authors or their respective institutions. None of the authors have any employment, consultancy, products in development, modified products, or other financial relationships related to the assay described in this manuscript.

We have reviewed the PLOS ONE policies on sharing data and materials. This does not alter our alter our adherence to PLOS ONE policies on sharing data and materials.

* E-mail: anders.berg@cshs.org
© 2021 Berg et al2021Berg et alhttps://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. http://dx.doi.org/10.13039/100000062National Institute of Diabetes and Digestive and Kidney Diseases R01 DK094486 Thadhani Ravi I. http://dx.doi.org/10.13039/100000062National Institute of Diabetes and Digestive and Kidney Diseases R01 HL133399 https://orcid.org/0000-0002-5736-0686 Berg Anders H. This study was funded by NIH/NIDDK award R01 DK094486 (RIT) and R01 HL133399 (AHB). The sponsor played no role in study design, data collection, analysis, or decision to publish.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T12:59:32.762307+00:00

DOI: 10.1371/journal.pone.0254158 · PMC8270209